Normalization of bronchial exocrine pathology after endobronchial treatment with ambroxol.
A clinical study was performed on nine adult in-patients suffering from chronic intercrisis bronchopneumopathy, to evaluate whether a local endobronchial treatment with ambroxol could be effective in stabilizing the secretory activity of bronchial glands modified by phlogistic injury. The patients underwent bronchoscopic examination and deep biopsy, before and after treatment with local medication of ambroxol every other day for 30 days. In addition to morphometric measurements, detailed histochemical examinations were performed on the secretion of mucous acinic and glandular excretory ducts. The trial proved that the treatment with ambroxol stimulates serous acini, restoring normal production of sulphomucins and also of mucous acini, increasing the metabolic activities of acid glycoproteins and proportionally curtailing the excessive synthesis of glycoproteins. Ambroxol can therefore be considered a mucoregulating drug.
D000328:Adult; D000368:Aged; D000551:Ambroxol / Q000494:pharmacology* / Q000627:therapeutic use; D001706:Biopsy; D001964:Bromhexine / Q000031:analogs & derivatives*; D001980:Bronchi / Q000187:drug effects* / Q000473:pathology; D001991:Bronchitis / Q000188:drug therapy* / Q000473:pathology; D001999:Bronchoscopy; D002908:Chronic Disease; D005088:Exocrine Glands / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism*; D009092:Mucous Membrane / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D052116:Sialomucins
D006023:Glycoproteins; D006025:Glycosaminoglycans; D009077:Mucins; D052116:Sialomucins; C001260:fucomucins; C012564:sulfomucin; D000551:Ambroxol; D001964:Bromhexine